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Cross-contamination between cell lines is a longstanding and
frequent cause of scientific misrepresentation. Estimates from
national testing services indicate that up to 36% of cell lines are of
a different origin or species to that claimed. To test a standard
method of cell line authentication, 253 human cell lines from banks
and research institutes worldwide were analyzed by short tandem
repeat profiling. The short tandem repeat profile is a simple
numerical code that is reproducible between laboratories, is inex-
pensive, and can provide an international reference standard for
every cell line. If DNA profiling of cell lines is accepted and
demanded internationally, scientific misrepresentation because of
cross-contamination can be largely eliminated.
Human cell lines are widely used in laboratory-based re-search. A significant proportion of this research is mislead-
ing, because the cell lines are of a different origin to that being
claimed (1). Cross-contamination of cell lines is a longstanding
problem and a repeated and frequent cause of scientific mis-
representation. This paper highlights the problem and describes
a method for its detection.
The first continuous cell line derived from a human cancer,
HeLa, was described in 1952 (2). Interspecies cross-contamina-
tion was soon described with HeLa (3, 4). Intraspecies cross-
contamination became detectable by 1967 with the development
of genetic markers, and it was discovered that HeLa cells had
probably cross-contaminated many other supposedly unique
human cancer cell lines (5). Despite a constant stream of reports
demonstrating evidence of inter- and intraspecies cross-
contamination (6–10), cross-contamination continues to occur
at an intolerably high rate (11–13). In a recent paper describing
new cell lines deposited at the German Cell Line Bank, 18% of
the 252 ‘‘new’’ cell lines were cross-contaminants (14).
There are many methods of detecting cell line cross-
contamination, including enzyme polymorphisms (15, 17), HLA
typing (8), karyotyping (18), and DNA polymorphisms (16). The
description of hypervariable regions within DNA led to
the concept of DNA fingerprinting (19), which was applied to the
authentication of human cell lines (20, 21). Locus-specific probes
were also used for the same purpose (22, 23). Although highly
informative, neither DNA fingerprinting nor locus-specific
probes provided data that could be exactly described or repro-
duced in a format suitable for a database of reference standards.
Until recently, there has been no standard inexpensive method
that could be universally applied to give a simple numerical code
that is reproducible in different laboratories.
Authentication and standardization are now possible by using
the short tandem repeat (STR) profiling techniques developed
for forensic applications (24). By using this approach, a number
of polymorphic STR loci are amplified by using commercially
available sets of primers. The PCR products are analyzed
simultaneously with size standards by using automated fluores-
cent detection techniques. The result is a simple numerical code
corresponding to the lengths of the PCR products amplified at
each locus, accurate to less than one base pair. By applying this
method to cell lines, every laboratory could either check the
authenticity of its cell lines or have them checked commercially
at a minimal cost, less than $200 each.
The aim of this study was to evaluate STR profiling for
detecting cross-contamination in samples obtained worldwide
and including likely cross-contaminating cell lines. The leading
cell banks from the U.S., Europe, Asia, and five large cancer
research institutes contributed samples. It was demonstrated that
STR profiling is an efficient and reliable means of detecting
cross-contaminated cell lines. These data could provide the basis
for an international reference standard for human cell lines. It
is to the benefit of all the scientific community that all cell lines
included in publications be authenticated by DNA profiling at
the time they are being used.
Materials and Methods
In a pilot study, DNA derived from 33 human cancer cell lines
was compared by using two STR profile multiplex systems:
Second Generation Multiplex (United Kingdom Forensic Sci-
ence Service) (25) and Powerplex 1 (Promega) (26). The infor-
mation on cell line identification and assortment obtained was
identical in the two systems, with the exception of a single pair
of samples that showed identical SGM profiles but an additional
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allele in one sample’s Powerplex 1 profile (at the D13S317 locus).
On the basis of the pilot study, the SGM STR multiplex was
chosen for an extended study.
For the extended study, 20 samples of DNA (1 mgyml) or cells
were requested from each of the major cell banks in the U.S.
(American Type Culture Collection, Manassas, VA; Coriell Cell
Repositories, Camden, NJ), Europe (European Collection of
Animal Cell Cultures, Salisbury, U.K.; Deutsche Sammlung von
Mikroorganismen und Zellkulturen, Braunschweig, Germany)
and Asia [The Institute of Physical and Chemical Research
(Japan) RIKEN, Tsukuba, Japan; Japanese Collection of Re-
search Bioresources, Tokyo] and from five cancer research
institutes carrying large stocks of human cancer cell lines. The
purpose of the project was explained to the 11 contributors, and
each was asked to provide 20 DNA or cell samples of their own
choosing. The analysis was blind and confidential for both the
contributing centers and the analytical center (LGC, Tedding-
ton, U.K.). No data on the claimed origin or the STR profile of
any cell line were released before the study was complete. A
small number of unexpected findings were made, and requests
were made for additional samples to be analyzed, in every case
with an identical result.
DNA was prepared from the cells, where necessary, by using
a commercial silica-gel-based purification kit (Qiagen, Crawley,
U.K.). The SGM kit comprises the six STR loci: tyrosine
hydroxylase, HUMTH01, 11p15.5; von Willebrand factor
(vWF), HUMVWFA31yA, 12p-12pter; D8S1179, chromosome
8; D21S11, 21q11.2–21q21; a Fibrinogen (FGA), HUMFIBRA,
4q28 and D18S51, 18q21.3 plus the sex chromosome marker
amelogenin, HUMAMGXyY, Xp22.1–22.3 and Yp11.2. SGM
amplifications contained 2 ng of target DNA in a 50-ml reaction
volume containing 13 PARR buffer (Cambio, Cambridge,
U.K.), 1.25 units AmpliTaq Gold DNA Polymerase (Perkin–
Elmer) and 200 mM of each dNTP (Amersham Pharmacia).
Samples were amplified by using the following conditions: 95°C
for 18 min, 30 cycles of 95°C for 30 seconds, 58°C for 75 seconds,
72°C for 15 seconds, and 72°C for 25 min. Primer concentrations
were 45 nM AMG 1y2, 87.5 nM TH01 1y2, 125 nM vWF 1y2,
560 nM D8S1179 1y2, 210 nM D21S11 1y2, 100 nM FGA 1y2,
and 100 nM D18S51 1y2. Samples that failed to give measurable
peaks at all loci were reanalyzed by using a different concen-
tration of DNA. A small proportion of samples failed twice but
were not processed further, as the aim of this study was to
determine the utility of the method under routine conditions.
All of the STRs used in this study have a tetranucleotide repeat
sequence, although intermediate sized alleles have been ob-
served for TH01, FGA, and D21S11. Multiplex PCR reactions
were carried out by using fluorescent dye-linked primers. La-
beled products were detected by electrophoretic size fraction-
ation on a Perkin–Elmer–ABI Prism 377 Genetic Analyser and
analyzed by using GENESCAN and GENOTYPER analysis software
(Perkin–Elmer). The end result for each cell line was an elec-
tropherogram, with each STR allele represented as one or more
peaks of the appropriate color (see Fig. 1).
The data were further analyzed to categorize peaks according
to their size in relation to an internal standard run (GS500,
Perkin–Elmer) in every lane in the gel. This analysis enabled
every peak to be allocated a size corresponding to the number
of repeat units present (e.g., TH01 9 has 9 AATG repeats and
results in a peak at 170.5 6 0.5 bp in SGM analysis). An
algorithm was developed to compare the allelic profiles, with
each profile (questioned profile) being checked against every
other profile (reference profiles) in the database. For each
comparison, the number of alleles present in both reference and
questioned profiles was scored and expressed as a percentage of
the total number of alleles in the questioned profile. The
principle can be seen operating in Table 1, where a consensus
profile is taken as the reference profile, and 16 examples of HeLa
cross-contaminants taken as questioned profiles.
The term cross-contamination is used in this study to indicate
misidentification of one cell line by another, rather than con-
tamination by a microbiological organism. Other tissue culture
terminology follows the internationally agreed nomenclature
(27), as used in the recently published United Kingdom Coor-
dinating Committee on Cancer Research guidelines for the use
of cell lines in cancer research (28).
Results
DNA from 253 human cell lines, including 33 cell lines in a pilot
study, was analyzed by STR profiling. Two further samples of
Vero cells, which are of monkey origin, were sent by different
centers and failed to amplify, as would be expected. One center
was excluded, because the DNA was too dilute for routine
analysis. Of the remaining 10 centers, 173y198 (87.4%) of
samples gave complete results within two runs. Including the
Fig. 1. Fully analyzed data derived from the
DNA of cell line HeLaS3, showing the blue, green,
and yellow amplified STR peaks and allele classi-
fications. These data are derived from a single
lane containing all the PCR products and the red
size standards. The PCR products and size stan-
dards are detected by laser excitation of the four
fluorescent dye labels by using an Applied Bio-
systems Prism 377 instrument. Profile quality is
assessed by two independent analysts, and the
peaks are then assigned allele values correspond-
ing to the number of repeat units by using GENE-
SCAN and GENOTYPER software. Allele designation
is based on fixed size windows (60.5 bp) derived
from multiple analyses of allelic ladder samples
containing all the commonly occurring alleles
(data not shown). The loci are as follows: blue
(Left to Right): HUMAMGXyY, HUMTH01,
D21S11, D18S51; green: D8S1179; yellow:
HUMVWFA31yA, HUMFIBRA.
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samples where partial data were obtained (up to two loci
missing), the success rate increased to 188y198 (94.9%). Three
centers sent cells rather than DNA, and the success rate for
complete analysis was 46y59 (78.0%) and for partial analysis was
55y59 (93.2%).
Matching Profiles. Among the 221 cell lines successfully analyzed,
139 different profiles were obtained (see Table 5, which is
published as supplemental data on the PNAS web site, www.
pnas.org). In some cases, the profiles were closely related,
differing by only one or two alleles. Seven groups, each con-
taining four or more identical or closely related profiles, were
identified blind, solely on the basis of the criterion that profiles
within a group should match at 80% or more of alleles, according
to the matching algorithm described in Materials and Methods.
Subsequent identification of cell lines within these groups con-
firmed that they represent HeLa (16 samples), T24 (9 samples),
K562 (8 samples), MRC5 (5 samples), HL60 (5 samples), 293 (7
samples), and MCF7 (4 samples). All examples of these lines
submitted in the study were identified by the blind analysis.
Sixteen examples of HeLa cells or its subline HeLaS3 or its
cross-contaminants (Hep2, Intestine 407, KB, J-111, HMV-1,
Chang Liver, and IMC-3) were included among the samples
submitted for analysis. Although these samples were shown to be
closely related by STR profiling, some were not identical. With
respect to a consensus profile, two contained an additional allele
at one locus, two showed a change of an allele, and seven showed
loss of an allele (Table 1). There were nine samples of another
common cross-contaminant, T24, and its cross-contaminants
EJ-1 and ECV304, MGH-U1, MGH-U2, HU456, and HU961T.
Again, the nine profiles were very similar, but five showed minor
changes with respect to the consensus sequence (Table 2).
Although some stocks of the J82 bladder cancer cell line have
been shown to be cross-contaminated with T24, the stocks tested
here and obtained from the originator were distinct. However,
it was discovered that another human bladder cell line, HU609,
was over 90% identical to J82.
To investigate the discriminatory power of the similarity
measure with an 80% threshold, the data were divided into two
groups, one containing all cell lines thought to be unrelated, and
the other containing all of the cell lines known to be of the same
origin. In this analysis, known kindreds were excluded by select-
ing parental profiles only, and from each subgroup of lines with
the same origin, one example was selected randomly for inclu-
sion in the unrelated cell lines. In the group of lines with the same
origin (total of 131), there were 41 subgroups, each containing
Table 1. STR profiles of HeLa lines
Trial
identification
Reported
name Comparison with consensus
Percent
match
SGM profile results
amg D18S1179 D21S11 D8S1179 FGA TH01 vWF
Consensus profile X 16 27, 28 12, 13 18, 21 7 16, 18
1 43 HeLa Identical 100 X 16 27, 28 12, 13 18, 21 7 16, 18
2 229 HeLa Identical 100 X 16 27, 28 12, 13 18, 21 7 16, 18
3 243 HeLa Identical 100 X 16 27, 28 12, 13 18, 21 7 16, 18
4 162 HeLa S3 Identical 100 X 16 27, 28 12, 13 18, 21 7 16, 18
5 181 HeLa S3 Identical 100 X 16 27, 28 12, 13 18, 21 7 16, 18
6 169 Hep II Identical 100 X 16 27, 28 12, 13 18, 21 7 16, 18
7 254 Intestine 407 Identical 100 X 16 27, 28 12, 13 18, 21 7 16, 18
8 14H HPC36M Identical 100 X 16 27, 28 12, 13 18, 21 7 16, 18
9 127 KB FGA (18) loss 100 X 16 27, 28 12, 13 21 7 16, 18
10 183 KB FGA (18) loss 100 X 16 27, 28 12, 13 21 7 16, 18
11 250 Chang Liver FGA (18) loss 100 X 16 27, 28 12, 13 21 7 16, 18
12 233 J-111 D8 (13) loss 100 X 16 27, 28 12 18, 21 7 16, 18
13 236 HeLa.P3 D21 (28) loss 100 X 16 27 12, 13 18, 21 7 16, 18
14 242 HMV-1 D8 (13) loss vWF (19) gain 91 X 16 27, 28 12 18, 21 7 16, 18, 19
15 256 IMC-3 D8 (13) loss vWF (18 to 19) change 90 X 16 27, 28 12 18, 21 7 16, 19
16 223 HeLa S3 D21 (29) gain 82 X 16 27, 28, 29 12 18, 21 7 17, 18
D8 (13) loss
vWF (16 to 17) change
amg, amelogenin.
Table 2. STR profiles of T24 cell lines
Trial
identification
Reported
name Comparison with consensus
Percent
match
SGM profile results
amg D18S1179 D21S11 D8S1179 FGA TH01 vWF
Consensus profile X 16, 18 29 14 17, 22 6 17
1 228 ECV304 Identical 100 X 16, 18 29 14 17, 22 6 17
2 222 EJ-1 (T24) Identical 100 X 16, 18 29 14 17, 22 6 17
3 9M MGH-U2 Identical 100 X 16, 18 29 14 17, 22 6 17
4 234 T24 Identical 100 X 16, 18 29 14 17, 22 6 17
5 5H HU456 FGA (17) loss 100 X 16, 18 29 14 22 6 17
6 10H HU961T FGA (17) loss 100 X 16, 18 29 14 22 6 17
7 18M MGH-U2 FGA (17) loss 100 X 16, 18 29 14 22 6 17
8 41 T24 vWF (19) gain 90 X 16, 18 29 14 17, 22 6 17, 19
9 7T T24 D8 (9) gain vWF (19) gain 82 X 16, 18 29 9,14 17, 22 6 17, 19
amg, amelogenin.
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between 2 and 16 cell lines. The unrelated group contained 127
lines, of which 9 were partial profiles.
The algorithm was applied to every possible pair of lines within
the unrelated group and to every known pair of cell lines within
the related group. The algorithm was applied twice for each pair,
with each line taken as the reference. This resulted in two
similarity measures for each pair, which were then averaged to
obtain a percentage similarity. The results are shown in Fig. 2 for
the complete profiles. These results are based on 264 pairs of
profiles for the same origin lines, of which 12 pairs resulted in a
similarity statistic of less than 80%. Nine of these were compar-
isons of HeLa sublines, all of which were greater than 70%
similar. Two were drug-resistant sublines of A2780. It has been
reported that drug-resistant sublines of A2780, in contrast to the
parental cell line, show strand-specific mismatch repair, which
may be the cause of the lack of similarity. One was a pair of cell
lines derived from normal and cancer tissue in the same indi-
vidual, which was only 78% similar because of three losses of
heterozygosity in the cancer cell line. Of the 6,903 pairs of lines
of supposedly different origin, only one resulted in a similarity
measure greater than 70%, the J82 and HU609 cell lines.
Viral Transformation. In this series, it was possible to make a
number of comparisons between cell lines before and after
transformation with viral genes. A MRC5 human fibroblast cell
line transformed with simian virus (SV) 40 had lost the Y allele
and one further allele but was otherwise identical to the un-
transformed cells (Table 3). In another pair of cell lines (trial
number 69, AGyNA0090, and trial number 70, AGyNA02804),
the SV40-transformed cells had gained one allele but were
otherwise identical. A pSV3neo-transformed subline (trial num-
ber 121) of the IBR.3 cell line (trial number 125) had lost an
allele. TTD1BR (trial number 124) has been transformed by
using different agents. A pSV3neotransformed subline (trial
number 138) had lost one allele and a heavily mutagenized (with
ultraviolet-C irradiation) subline had lost a different allele,
whereas an Epstein–Barr virus-transformed lymphoblastoid cell
line (trial number 133) from the same individual was identical to
TTD1BR.
Drug-Resistant Lines. Sublines with high levels of drug resistance
can be obtained by growing the cells over long periods (usually
12 months or more) in the presence of increasing concentrations
of the drug of interest. This treatment can lead to major changes
in karyotype. The drug-resistant sublines were shown to be
related to the parental cells within the limits of the algorithm,
with the exception of the A2780 ovarian cancer cell lines.
Familial Studies. STR profiling is now used routinely to determine
family relationships. Some DNA samples from cell lines derived
from related individuals were included. For example, samples 62,
63, and 66 are father, mother, and daughter, respectively, and the
observed inheritance of alleles within the STR profile is con-
sistent with this claim. Samples 126 and 137 are the father and
mother of siblings 122, 129, 131, and 140, and again the data are
consistent.
Peak Height Imbalance. For normal diploid human DNA, STR
profiling will usually produce profiles with approximately equal
peak heights for both alleles at heterozygous loci, although more
variation may be seen between loci. Many samples in this study
showed large height differences between peaks at heterozygous
Fig. 2. Histogram showing relative frequency of the simi-
larity measure at 10% intervals for the 6,903 unrelated pairs
of cell lines (black bars) and 264 pairs of cell lines of the same
origin (open bars).
Table 3. MRC5 cell lines transformed with viral genes
Trial
identification Reported name
Comparison with
consensus
Percent
match
SGM profile results
amg D18S1179 D21S11 D8S1179 FGA TH01 vWF
Consensus profile X, Y 15, 21 31.2 13 21, 23 8 15
132 MRC5y28 Primary untransformed cell line Identical 100 X, Y 15, 21 31.2 13 21, 23 8 15
139 MRC5neoAy48 PSV3 neo-transformed Identical 100 X, Y 15, 21 31.2 13 21, 23 8 15
180 MRC5 Identical 100 X, Y 15, 21 31.2 13 21, 23 8 15
160 MRC5 Identical 100 X, Y 15, 21 31.2 13 21, 23 8 15
200 MRC-5 FGA (21) loss 90 X, Y 15, 21 31.2 13 23 8 15
135 MRC SV1 SV40-transformed FGA (21) loss amg (Y) loss 80 X 15, 21 31.2 13 23 8 15
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loci. This preferential amplification of one allele over the other
may indicate gene duplication events, aneuploidy, or a chimeric
cell population. Data on relative peak heights, evident from the
electropherograms (e.g., see Fig. 1), could provide useful addi-
tional information in identifying related cell lines.
Loss of Heterozygosity. The STR loci used were chosen on the
basis of their high degree of heterozygosity. In STR profiles from
200 Caucasian adults randomly selected from samples submitted
to LGC for forensic analysis, heterozygosity at the six STR loci
ranged from 79.1 to 87.8%. In this series of transformed and
cancer cell lines, the degree of heterozygosity was far lower,
ranging from 48.2 to 70.3% (see Table 4). Although these figures
are biased by multiple representation of the same cell lines, they
still indicate additional loss of heterozygosity. This finding is
consistent with the neoplastic origin of most of the cell lines
included.
Three or More Alleles at a Locus. The occurrence of three detect-
able alleles at one locus is a rarity among normal human SGM
profiles [’1 in 1,000 individuals (J.A.T., unpublished work)].
There were 18 examples of triple peaks in this series, with
examples at every locus except TH01 (see Table 4). A leukemia
cell line, MOLT-4, showed three alleles at two loci and an
ovarian cancer cell line, SKOV-3, showed three alleles at three
loci. Two samples of the lymphoma cell line, U937, were
identical, except one had two and the other four alleles at the
vWF locus. As with peak height imbalance, multiple alleles may
be a result of genuine trisomy or may represent other gene
duplication events or cell mixtures.
Cell Mixtures and Somatic Cell Hybrids. Three parental cell lines and
eight distinct somatic cell hybrids were analyzed blind. The
results were entirely consistent, although some alleles were lost
in the somatic cell hybrids, as might be expected. Knowing the
origin of the parent cells, STR profiling could be used to confirm
the derivation of the somatic cell hybrids (data not shown). Two
cancer cell lines and mixtures ranging from 1 to 99% of each cell
line were tested blind. In this limited study, objective evidence
for two profiles was not observed in mixtures containing less than
10% of the smaller fraction (data not shown).
Discussion
STR profiling was evaluated as a simple method for cell line
identification suitable for the establishment of reference geno-
types. Two hundred and fifty-three cell lines from international
cell banks and cancer research institutes worldwide were ana-
lyzed. It was demonstrated that this method can provide a
universal reference standard for human cell lines. If this ap-
proach is applied internationally by using a common set of STR
primers, cross-contamination of human cell lines will be readily
detectable and such misrepresentation almost entirely elimi-
nated, except as a result of deliberate fraud.
The methodology used deliberately did not set out to custom-
ize analysis for different sample or cell types, and so the results
illustrate the success rate for obtaining complete profiles under
routine circumstances at minimal cost. Samples with low DNA
concentrations could have been processed further, as is standard
for certain forensic samples, or another sample obtained. STR
profiles should be readily obtainable for all human cell lines.
Where appropriate primers are available, DNA profiling can
be applied to DNA samples from all species. In addition, human
specific STR primers, such as those used in this study, could
provide rapid confirmation that particular human chromosomes
are present in somatic cell hybrids between human cells and cells
of other species. Within an established cell line designation,
analysis of additional STR loci can be used to characterize
subline specific markers if required, as shown in the pilot study.
The STR profiles indicate that the HeLa sublines are not
identical, and that there are both gains and losses of alleles,
which may reflect the phenotypic differences observed in dif-
ferent laboratories. For the same strain of each cell line to be
used worldwide, the international cell banks will need to agree
to have a common stock.
Apart from simple cross-contamination, we checked whether
viral transformation or long-term exposure to chemotherapeutic
drugs would produce sublines that appeared to be distinct by
STR profiling. However, the differences between the parental
and derived cell lines were no greater than those between the
HeLa sublines, and in all cases the sublines were identified as
being closely related to the parental line.
Electropherograms provide information about the relative
heights of peaks at heterozygous loci, which may reflect the
number of copies of that allele present (Fig. 1). This information
is lost in the simple numerical code. The code could be modified
to indicate the relative peak height at each locus, for example by
indicating the ratio of the two peaks as a bracketed suffix, e.g.,
TH01 7, 9 (1:1.8). Large differences in the height of two peaks
at the same locus can be caused by a variety of reasons, including
cell mixtures, differential amplification efficiency between het-
erozygous loci (for example because of a mutation in the primer
binding site), or the presence of additional copies of one allele.
Many of the samples in this study showed large differences in
peak height at one or more loci. This finding is typical of cancer
cells and reflects their relatively high genetic instability com-
pared with normal cells.
For normal human DNA, STR profiling will show two alleles
at most loci, as expected for highly polymorphic loci in a diploid
genotype. Additional alleles at a locus are rarely seen in normal
profiles but theoretically can occur by trisomy, gene duplication,
or mixed populations of cells or hybrids. If most of the loci show
more than two peaks, this is an indication of an hybrid or mixture
of cells, whereas single loci with more than two peaks are more
likely explained by trisomy or gene duplication events.
Because the loci were chosen on the basis of their high degree
of heterozygosity in human populations, relatively few homozy-
gous loci with single alleles would be expected. The significantly
elevated levels of homozygosity observed in this study are
consistent with the characteristic loss of heterozygosity, common
in many cancer cells, particularly in the later stages of cancer
progression from which almost all cancer cell lines are derived.
At the TH01 locus, the incidence of homozygosity increased
from about 20 to over 50%.
STRs are subject to mutation at a relatively high rate: in 10,844
parentychild allelic transfers at 9 loci, 23 mismatches were
observed, 22 of which were because of a single-step mutation
Table 4. Frequency of genetic changes in the general population of Caucasian adults and in the cell lines in this series
D18S1179 D21S11 D8S1179 FGA TH01 vWF
Heterozygosity in this trial 59.9% 69.8% 70.3% 69.9% 48.2% 61.5%
Heterozygosity in Caucasian adults 85.7% 82.7% 82.7% 87.8% 79.1% 82.7%
Occurrence of three alleles in this trial 2y177 6y192 4y192 3y183 0y193 5y192
Occurrence of four alleles in this trial 0 0 0 0 0 1y192
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(29). It is generally accepted that replication slippage (30) is the
major mechanism causing new mutations in microsatellites (29).
STR loci have a higher frequency of polymorphism than single
nucleotide polymorphisms and are the preferred option for
forensic applications, but technological developments in the
near future will provide rapid automated DNA profiling on
arrays.
If DNA profiling of cell lines becomes accepted as normal
practice, then editors of scientific journals could require authors
to confirm that all cell lines used have been checked for
authenticity during the period of the study. This analysis could
become a prerequisite for publication, so that the problem of cell
line cross-contamination can be reduced to a minimum in the
future. This advance will be of great benefit to the scientific
community, which can in future confidently develop or extend
cell culture-based studies from other researchers without fear of
false premises and without their own results being attributable to
contamination.
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